Processa Pharmaceuticals (PCSA) Assets Average (2013 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Assets Average came in at $6.2 million in Q1 2026, up 53.44% YoY from $4.0 million in Q1 2025, and down 19.9% on a QoQ basis from $7.7 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Assets Average (2013 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 14 years of Assets Average data on file, last reported at $6.2 million in Q1 2026.
- Quarterly Assets Average rose 53.44% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (up 53.44% YoY) and the FY2025 annual result came in at $5.5 million, up 22.48% from the prior year.
- Assets Average retreated to $6.2 million in Q1 2026, from $7.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $25.4 million in Q1 2022 to a low of $4.0 million in Q1 2025.
- A 5-year average of $10.5 million and a median of $7.9 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average tumbled 58.53% — and 2025, when it soared 88.44%.
- Tracing PCSA's Assets Average over 5 years: stood at $13.6 million in 2022, then sank by 49.06% to $6.9 million in 2023, then slumped by 41.08% to $4.1 million in 2024, then soared by 88.44% to $7.7 million in 2025, then retreated by 19.9% to $6.2 million in 2026.
- The last three Assets Average figures came in at $6.2 million (Q1 2026), $7.7 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | 3.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.17 Mn |
| Dec 31, 2025 | 7.70 Mn |
| Sep 30, 2025 | 7.88 Mn |
| Jun 30, 2025 | 6.50 Mn |
| Mar 31, 2025 | 4.02 Mn |
| Dec 31, 2024 | 4.09 Mn |
| Sep 30, 2024 | 6.27 Mn |
| Jun 30, 2024 | 8.77 Mn |
| Mar 31, 2024 | 7.87 Mn |
| Dec 31, 2023 | 6.93 Mn |
| Sep 30, 2023 | 9.09 Mn |
| Jun 30, 2023 | 11.26 Mn |
| Mar 31, 2023 | 10.53 Mn |
| Dec 31, 2022 | 13.61 Mn |
| Sep 30, 2022 | 20.13 Mn |
| Jun 30, 2022 | 22.98 Mn |
| Mar 31, 2022 | 25.38 Mn |
| Dec 31, 2021 | 27.74 Mn |
| Sep 30, 2021 | 30.08 Mn |
| Jun 30, 2021 | 32.24 Mn |